First Time Loading...

Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 28.28 USD -1.67% Market Closed
Updated: May 4, 2024
Section:
 

Relative Value

The Relative Value of one RPRX stock under the Base Case scenario is 49.62 USD. Compared to the current market price of 28.28 USD, Royalty Pharma PLC is Undervalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RPRX Relative Value
Base Case
49.62 USD
Undervaluation 43%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.2
P/S
P/S
Price to Sales
7.2
vs History
83
vs Industry
20
Median 3Y
9.9
Median 5Y
10.1
Industry
2.4
Forward
6.3
More Details
14.9
P/E
P/E
Price to Earnings
14.9
vs History
77
vs Industry
32
Median 3Y
43.7
Median 5Y
41.1
Industry
22.9
Forward
7.3
More Details
5.7
P/OCF
P/OCF
Price to OCF
5.7
vs History
89
vs Industry
44
Median 3Y
10.7
Median 5Y
11
Industry
17.1
More Details
407.6
P/FCFE
P/FCFE
Price to FCFE
407.6
vs History
4
vs Industry
2
Median 3Y
36.9
Median 5Y
34.2
Industry
23.2
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
89
vs Industry
32
Median 3Y
3.9
Median 5Y
4
Industry
2.1
More Details
9.3
EV/S
EV/S
Enterprise Value to Sales
9.3
vs History
77
vs Industry
16
Median 3Y
11.8
Median 5Y
11.9
Industry
2.6
Forward
8.1
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.1
More Details
14.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.6
vs History
73
vs Industry
27
Median 3Y
20
Median 5Y
19.1
Industry
13.6
Forward
8.6
More Details
14.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.6
vs History
73
vs Industry
32
Median 3Y
20
Median 5Y
19.1
Industry
17
Forward
10
More Details
7.3
EV/OCF
EV/OCF
Enterprise Value to OCF
7.3
vs History
89
vs Industry
42
Median 3Y
12.4
Median 5Y
12.8
Industry
15.8
More Details
25
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
25
vs History
53
vs Industry
18
Median 3Y
26.1
Median 5Y
26.1
Industry
17.6
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
87
vs Industry
48
Median 3Y
1.8
Median 5Y
1.9
Industry
1.9
More Details

Multiples Across Competitors

RPRX Competitors Multiples
Royalty Pharma PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Royalty Pharma PLC
NASDAQ:RPRX
16.9B USD 7.2 14.9 14.6 14.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
697.9B USD 20.5 133.2 60.2 69.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.2 33 36
US
Johnson & Johnson
NYSE:JNJ
357.8B USD 4.4 8.8 11.8 15.5
US
Merck & Co Inc
NYSE:MRK
323.8B USD 5.3 140.4 33.4 53
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.4 140.7 225.6
CH
Novartis AG
SIX:NOVN
179.8B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
173.2B CHF 3 15.1 8.6 10.2
US
Pfizer Inc
NYSE:PFE
155.7B USD 2.7 73.5 11 16.2
P/E Multiple
Earnings Growth
US
Royalty Pharma PLC
NASDAQ:RPRX
Average P/E: 53.8
14.9
142%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
133.2
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.2
84%
US
Johnson & Johnson
NYSE:JNJ
8.8
-20%
US
Merck & Co Inc
NYSE:MRK
140.4
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.4
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.1
26%
US
Pfizer Inc
NYSE:PFE
73.5
680%

See Also

Summary
RPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RPRX stock valuation using valuation multiples.
Wall Street Estimates
RPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.